LUXLung5_1A: LUXLung5, figure 1A

LUXLung5_1AR Documentation

LUXLung5, figure 1A

Description

Kaplan-Meier digitized data from LUXLung5, figure 1A (PMID 26646759). A reported sample size of 220 for a primary endpoint of PFS in lung cancer.

Usage

LUXLung5_1A

Format

A data frame of 202 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (afatinib_paclitaxel, chemo)

Source

Schuler M, Yang JC-H, Park K, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 2016; 27: 417–23.

Examples

summary(LUXLung5_1A)

kmplot(LUXLung5_1A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.